The mechanism of action of kefir and its effect on the motility of breast and colorectal cancer cells. (c2013) by Khoury, Nathalie El
 
 
 
LEBANESE AMERICAN UNIVERSITY 
 
 
The Mechanism of Action of Kefir and its Effect on the 
Motility of Breast and Colorectal Cancer Cells 
 
 
By 
Nathalie El Khoury 
 
 
A thesis submitted in partial fulfilment of the 
requirements for the degree of Master of Science in 
Molecular Biology 
 
 
 
 
 
 
School of Arts and Sciences 
May 2013 
 
 
 ii   
 
 
 
 iii   
 
 
 
 
 iv   
 
 
 
 
 v   
 
THESIS COPYRIGHT RELEASE FORM 
LEBANESE AMERICAN UNIVERSITY NON-EXCLUSIVE DISTRIBUTION LICENSE 
By signing and submitting this license, you (the author(s) or copyright owner) grants to 
Lebanese American University (LAU) the non-exclusive right to reproduce, translate (as 
defined below), and/or distribute your submission (including the abstract) worldwide in 
print and electronic format and in any medium, including but not limited to audio or 
video. You agree that LAU may, without changing the content, translate the submission 
to any medium or format for the purpose of preservation. You also agree that LAU may 
keep more than one copy of this submission for purposes of security, backup and 
preservation. You represent that the submission is your original work, and that you have 
the right to grant the rights contained in this license. You also represent that your 
submission does not, to the best of your knowledge, infringe upon anyone's copyright. If 
the submission contains material for which you do not hold copyright, you represent that 
you have obtained the unrestricted permission of the copyright owner to grant LAU the 
rights required by this license, and that such third-party owned material is clearly 
identified and acknowledged within the text or content of the submission. IF THE 
SUBMISSION IS BASED UPON WORK THAT HAS BEEN SPONSORED OR 
SUPPORTED BY AN AGENCY OR ORGANIZATION OTHER THAN LAU, YOU 
REPRESENT THAT YOU HAVE FULFILLED ANY RIGHT OF REVIEW OR 
OTHER OBLIGATIONS REQUIRED BY SUCH CONTRACT OR AGREEMENT. 
LAU will clearly identify your name(s) as the author(s) or owner(s) of the submission, 
and will not make any alteration, other than as allowed by this license, to your 
submission.  
Name:  Nathalie El Khoury 
 
Signature:                                                                                                                                                                
 
       Date: 14/05/2013 
 
 
 
 
 
 
Date: May 28, 2013 
 vi   
 
PLAGIARISM POLICY COMPLIANCE STATEMENT 
 
 
I certify that I have read and understood LAU’s Plagiarism Policy. I understand that failure 
to comply with this Policy can lead to academic and disciplinary actions against me. This 
work is substantially my own, and to the extent that any part of this work is not my own I 
have indicated that by acknowledging its sources. 
 
 
 
Name: Nathalie M. El-Khoury 
 
 
Signature:      
 
 
 
       Date: 14/05/2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date: May 28, 2013 
 vii   
 
ACKNOWLEDGEMENTS 
 
I would like to express my gratitude to both of my advisors, Dr. Sandra Rizk for 
her continuous support, encouragement, and trust, and Dr. Mirvat El-Sibai for her 
continuous guidance, advices, and for everything she has have taught me. 
 
My appreciation extends to the entire faculty that have taught me especially Dr. 
Roy Khalaf and the committee members Dr. Brigitte Wex and Dr. Mohammad Mroueh. 
Their acceptance for being part of my thesis committee is of high appreciation. 
 
Furthermore, I would like to acknowledge with much appreciation the role of my 
friends at LAU with whom I share a lot of unforgettable memories especially Perla 
Zgheib, Anita Nasrallah, and Bechara El Saykali. 
 
Last but not least, my deepest gratitude goes to my family, my mom and dad, who 
always support and trust me with every step that I take. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 viii   
 
The Mechanism of Action of Kefir and its Effect on the Motility of 
Breast and Colorectal Cancer Cell Lines 
 
Nathalie M. El-Khoury 
 
ABSTRACT 
 
Kefir which is a fermented milk product originating from the Caucasus 
Mountains is gaining increasing popularity due to its attribution in preventing or curing 
many chronic diseases among them cancer. Previous studies have focused on the anti-
tumoral activity of kefir in vivo yet not extensive studies have been performed to 
elucidate its mechanism of action. Till now kefir is known to modulate intestinal 
microbiota, modulate the activity of immune system cells, and suspected to induce 
apoptosis in cancer cells in vivo. Recent studies have focused on the direct effect of kefir 
cell-free fractions on cancer cells in vitro. Earlier work in our lab has shown that cell-
free fractions of kefir have anti-proliferative and pro-apoptotic effect on Caco-2 and HT-
29 colorectal adenocarcinoma cells. In this study, we aim to determine a possible 
mechanism of action of kefir and to study its effect on the motility of colorectal and 
breast cancer cell lines. Results from the reverse-transcription PCR experiment have 
shown that kefir decreases the expression of TGF-α and TGF-β1 in HT-29 cells in a dose 
dependent manner. An increase in the production of both cytokines is usually associated 
with neoplastic transformation. Western blot assay results confirmed the previously 
observed increase in apoptosis as it showed an increase in Bax:Bcl-2 expression upon 
kefir treatment. Also an increase in p53 independent-p21 expression was observed in 
HT-29 cells upon kefir treatment which would explain the anti-proliferative effect of 
kefir. Furthermore, results from the time-lapse movies, wound-healing, and invasion 
assays showed no effect on the motility of colorectal (Caco-2 and HT-29) as well as 
breast (MCF-7 and MB-MDA-231) cancer cells upon kefir treatment.  
 
Keywords: Colorectal Cancer, Breast Cancer, Kefir, Proliferation, Apoptosis, Cell 
Motility, Cell Invasion. 
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Chapter I 
Literature Review 
 
1.1. Colorectal cancer 
1.1.1. Incidence and statistics 
In 2013, the American Cancer Society (ACS) ranked colorectal cancer (CRC) as 
the third leading cause of cancer-related mortalities in the United States in both men and 
women. In 1975, 60 new cases of colorectal cancer per 100,000 people were diagnosed 
every year in the United Stated, but this rate has declined by 2007 to approximately 45 
new cases per 100,000 individuals. Moreover, the mortality rates decreased from 28 in 
1975 to 17 by 2007 per 100,000 individuals (The National Cancer Institute, 2010). In 
2013, it is estimated that 142,820 new cases of CRC will be diagnosed among which 
50,830 death cases will arise (Siegel, Naishadhan, & Jemal, 2013). 
 
1.1.2. Types 
Among all CRC, 72% arise in the colon and the remaining 28% arise in the rectum 
(National Cancer Institute, 2010). Adenocarcinoma, the cancer caused by the mucus-
secreting epithelial cells of the colon, account for more than 95% of CRC. Other less 
common tumors that can originate in the colon or rectum might include carcinoid tumors 
formed from neuroendocrine cells of the colon, lymphomas caused by immune system 
cells that reside in the colon, as well as sarcomas caused by different connective tissues 
including muscle and blood vessel cells. Therefore, when medical doctors refer to CRC 
they are most probably referring to adenocarcinomas (American Cancer Society, 2013). 
The sequence of events leading to the formation of CRC takes place over a period of 10-15 
years and involves the accumulation of genetic mutations and chromosomal aberrations 
induced by several environmental factors as well as inherited genetic mutations (Hoff, 
Foerster, Vatn, Sauar, & Larsen, 1986; Hamilton, 1993; O’Brien, et al., 1993). The 
extended period of time leading to CRC allows sufficient time for chances to screen, 
properly interfere, and to potentially save the lives of more patients. 
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1.1.3. Screening and Diagnosis 
By the time people are diagnosed with CRC, 25% of patients would have already 
developed metastasis. Among these patients with metastatic colorectal cancer, 50% will 
survive (Kufe, et al., 2003). This necessitates the need for tools and techniques to screen 
for and diagnose early stage cancer as well as adenomatous polyps. 
 
In 2008, the U.S. Preventive Services Task Force recommended that individuals 
between the ages of 50 and 75 years screen for colorectal cancer using three different 
screening methods to diminish the risk of death from CRC.  The fecal occult blood testing 
is recommended to be performed annually. Two other tests are accompanied by a small 
risk of compilations, therefore sigmoidoscopy is advised every five years, and 
colonoscopy is recommended every ten years (Pignone & Sox, 2008).  
 
1.1.4. Current cures 
Surgical treatment remains the best option for the treatment of colorectal cancer 
but in a large number of cases solely it is not the ideal treatment since its outcome 
depends on the extent of the disease (Cunningham, et al., 2010). On the other hand, 
radiation therapy is not used as a standard treatment for CRC, yet it is used along with 
chemotherapy preoperatively (Latkauska, et al., 2010). 
Significant successes have been achieved by chemotherapeutic drugs in the 
treatment of CRC to an extent that the survival of patients with CRC can now be extended 
by nearly two years (Wolpin & Mayer R, 2008). 5-Fluorouracil (5-FU) was one of the 
earliest and most commonly used drugs for the treatment of CRC (Sobrero, Guglielmi, 
Grossi, Puglisi, & Aschele, 2000). Later on, Oxaliplatin and Leucovorin have shown to 
enhance the survival of patients when added to 5-FU (Becouarn, et al., 1998). Irinotecan, 
an inhibitor of topoisomerase I, is able to enhance the overall survival of patients with 
metastatic CRC when administered with leucovorin and 5-FU (Fuchs, et al., 2007). 
Recently, focus has been directed toward targeted therapy. For example, 
Bevacizumab, a monoclonal antibody that binds the Vascular Endothelial Growth Factors 
(VEGFs) which play a role in blood vessel formation, has shown to improve the survival 
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of patients when combined with chemotherapeutic drugs (Ferrara & Gerber, 2003). The 
epidermal growth factor receptor (EGFR) is also an important target in the treatment of 
colorectal cancer and the most effective antibodies used against it are cetuximab and 
panitumumab (Messersmith & Hidalgo, 2007). Yet the limitation of these targeted 
therapies lies in the fact that in rare cases tumors develop mutations in the intra-signaling 
pathways of EGFR rendering the treatment ineffective (Berg & Soreide, 2012). 
 
1.2. Breast cancer 
1.2.1. Incidence and statistics 
In 2012, the American Cancer Society ranked breast cancer as the second deadliest 
cancer in women in the United States. Breast cancer rarely affects men; it is 100 times 
more common in women (American Cancer Society, 2012). Between 2005 and 2009 on 
average 124.3 cases of breast cancer were diagnosed per 100,000 women yearly (National 
Cancer Institute, 2013). 
 
1.2.2. Types 
In situ carcinomas of the breast are of two types, ductal carcinoma in situ (DCIS) 
or lobular carcinoma in situ (LCIS). These types of carcinomas can not invade surrounding 
tissues and do not metastasize. LCIS do not develop into invasive LC but may be a marker 
of an increased risk for invasive DC or LC development in any of the breasts (Simpson & 
Wilkinson, 2004). Yet, DCIS was shown to be a precursor to invasive DC. Invasive 
lesions have the ability to penetrate the basement membrane and spread into adjacent 
stroma in the breast and therefore have the potential to metastasize. Among invasive breast 
cancer 70 to 80% are invasive DC and almost 10% are invasive LC, the remaining are less 
common histologic types such as apocrine, tubular, medullary, mucinous, and papillary 
(Simpson & Wilkinson, 2004). A classification based on gene expression profiling done in 
2000 by Perou et al. identified five subgroups of breast cancer they are basal epithelial-like 
group, Her-2 (Human Epidermal Growth Factor Receptor-2) overexpressing, normal 
breast like group, and ER positive luminal A and B. These subtypes have differential 
survival rates, prognosis, and response to different treatments. Also, from a clinical 
perspective, breast cancer is subdivided into three categories, the HR-positive (Hormone-
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receptor positive) cells that express estrogen and progesterone receptors, Her-2 
overexpressing cells, and the remaining are known as triple negative breast cancer 
(TNBC) since they lack any of these three receptors (Perou, et al., 2000; Sorlie, et al., 
2001) 
 
1.2.3. Screening and Diagnosis 
In 2012, the American Cancer Society in 2012 recommended that women above 
the age of 40 do annual mammograms, an X-ray for the breast, in order to detect early 
breast cancer. It also recommends a clinical breast exam (CBE) to be performed every 
three years for women between the ages of 20 and late 30s and annually for women above 
the age of 40 by a health care professional. Breast self-examination (BSE) is also 
recommended by the ACS for woman above the age of 20. For women who are at a high 
risk (eg. having a BRCA1, Breast cancer 1, and BRCA2, Breast cancer type 2 susceptibility 
protein) an MRI (Magnetic resonance imaging) along with mammogram is recommended 
annually.  
 
1.3.4. Current cures 
Lumpectomy, the removal of the cancerous tissues, or mastectomy, the removal of 
the entire breast, are ideal for the treatment of early breast cancer, yet micro-metastatic 
cells may remain and cause recurrence (Hassan, Ansari, Spooner, & Hussain, 2010). 
Therefore, chemotherapy is regularly used as an adjuvant six weeks after surgery. The 
most commonly used combination used is fluorouracil, adriamycin, cyclophosphamide or 
fluorouracil, epirubicin, and cyclophosphamide. Also, postoperative locoregional radiation 
shows reduced risk of recurrence and mortality rates (Whelan, Julian, Wright, Jadad, & 
Levine, 2000). 
 
Targeted therapy is widely used in the treatment of breast cancer. An important 
example is Trastuzumab (Herceptin), a monoclonal antibody that targets the Her-2 
receptor, usually overexpressed in 20% of breast cancers, when added to chemotherapy 
decreased the recurrence of the disease by 53% (Romond, at al., 2005). Tamoxifen, an 
estrogen receptor antagonist in the breast, significantly decreases the death rate for ER-
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positive (Estrogen receptor-positive) breast cancer, the most common type of breast cancer 
(EBCTCG, 2005). Megestrol acetate, a derivative of progesterone, is also used for the 
treatment of advanced breast cancer (Allegra, 1987). Ovarian ablation, oophorectomy, is 
also used following hormone therapy mainly to treat metastatic breast cancer in pre-
menopausal women (Pater & Parulekar, 2003). TNBC cells which do not express the 
estrogen, progesterone, or the Her2 receptors on their plasma membrane do not respond 
well to targeted therapy is usually treated with chemotherapeutic drugs (Vaklavas & 
Forero-Torres, 2011).  
 
Despite the fact that significant improvements have been made in the treatment of 
early breast cancer, a major challenge in breast cancer remains in the treatment of 
metastatic cases (Hassan, Ansari, Spooner, & Hussain, 2010) 
 
1.3. Signaling pathways in cancer 
 1.3.1. Bcl-2 family of apoptosis regulatory proteins 
The Bcl-2 (B-cell lymphoma 2) protein family plays a crucial role in apoptosis 
through its anti-apoptotic as well as pro-apoptotic proteins. The expression of proteins in 
this family are dynamically balanced and alterations in their expression leads to either 
enhancement or prevention of cell death (Ola, Nawaz, & Ahsan, H, 2011). Members of 
this family possess Bcl-2 homology domains known as BH1, BH2, BH3, and BH4 which 
are necessary for the formation of heterodimeric binding among members of the Bcl-2 
family (Danial & Korsmeyer, 2004). Antiapoptotic proteins of this family include Bcl-2, 
Bcl-xL, and Bcl-w. On the other hand, the pro-apoptotic include Bak and Bax or those that 
only possess the BH3 domain such as Puma (Promoter upregulated modulator of 
apoptosis) and Bid  (Bcl-2 interacting domain death agonist) (Wang, Yin, Chao, Milliman, 
& Korsmeyer, 1996; Brunelle & Letai, 2009). In normal physiological conditions, Bak, a 
proapoptotic protein, is present in the outer mitochondrial membrane OMM in its inactive 
form while Bax is inactive in the cytosol (Youle & Strasser, 2008). Following stimulation 
by an apoptotic signal, Bax is translocated to the OMM and leads to the formation 
Bax/Bak homodimers that leads to the formation of pores in the OMM and causes the 
leakage of proteins from the intermembrane space into the cytosol such as Smac (Second 
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mitochondrial activator of caspases) and cytochrome c. Cytochrome c is then activated 
through its interaction with dATP and Apaf-1(Apoptosis protease-activating factor-1) 
leading to the formation of apoptosome that causes the activation of caspases that cleavage 
various components required for the proper functioning of the cell (Yethon, et al. 2003; 
Wei, et al 2001). In the absence of apoptotic signals, antiapoptotic members of the bcl-2 
prevent any leakage from the mitochondria by preventing the oligomerization of the 
proapoptotic members of the Bcl-2 family (Youle & Strasser, 2008). Therefore, the 
regulation of activity and expression of BH3-only proteins is critical in the induction of 
apoptosis. Generally, the proportion of pro-survival to pro-apoptotic proteins of the Bcl-2 
family appears to regulate the sensitivity of the cell to the apoptotic signal (Ola, et al., 
2011). 
 
1.3.2. Roles of p53 and p21 in apoptosis 
P53 (Protein 53) is a widely known transcription factor that localizes mostly in the 
nucleus and is able to induce the expression of several genes that lead to DNA damage 
repair, cell cycle arrest, and apoptosis (Oren & Rotter, 1999; Vousden & Lu, 2002). In 
normal physiology, the expression of p53 is maintained at a low level through its 
proteasomal degradation induced by the ubiquitin protein ligase MDM-2 (Mouse double 
minute 2 homolog) (Kubbutat, Jones, & Vousden, 1997). When DNA damage occurs, p53 
becomes active by undergoing post-translational modifications which increase its stability 
and allows its accumulation in the nucleus (Prives & Hall, 1999). When active, p53 
induces the expression of a set of genes involved in DNA damage repair and cell cycle 
arrest. After the DNA is repaired, the cell returns to its normal cell cycle. But when the 
DNA damage is severe and beyond repair, p53 would then induce apoptosis in the cell (El-
Deiry, 2003). P53 exerts its effect through several target genes among them the cell cycle 
inhibitor p21.  P21 binds to the cyclin-dependent kinase-2 and prevents it from 
phosphorylating the retinoblastoma protein pRB. The inactive pRB will bind transcription 
factors of the E2F protein and constrain it in an inactive form which will prevent the cell 
from proceeding to the S phase of the cell cycle and remain in the G1 phase. (Harper, 
Adami, Wei, Keyomars, & Elledge, 1993). However, p21 can also be induced in a p53-
independent manner whether induced by DNA damage or not (Macleod, et al., 1995). 
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Another target of p53 is MDM-2 which is needed to negatively regulate the expression of 
p53 levels (Barak, Juven, & Haffner, 1993). P53 also induces its apoptototic effect by 
modulating the activity and expression of pro-apoptptic proteins of the Bcl-2 family such 
as Bax, PUMA, as well as others (Selvakumaran, et al., 1994; Yu, Zhang, Hwang, Kinzler, 
& Vogelstein, 2001).  
 
1.3.3. TGF-alpha signaling pathway 
Transforming growth factor alpha (TGF-α) is a member of the epidermal growth 
factor family EGF (Salomon, Brandt, Ciardiello, & Normanno, 1995). It shares a 40% 
homology in sequence with EGF and competitively compete for its receptor which is the 
Epidermal Growth Factor Receptor EGFR. EGFR belongs to the ErbB protein family of 
tyrosine kinases that play a significant role in cell survival, proliferation, motility, 
angiogenesis, and adhesion (Arteaga, 2003). Receptor activation triggers a downstream 
signaling pathways including the phosphoinositide 3-kinase (PI3K), the KRAS-BRAF-
MEK-ERK pathway, the  phospholipase C gamma, and the STAT signaling pathway 
(Yarden & Sliwkowski, 2001; Baselga & Albanell, 2002) 
 
To maintain proper cell homeostasis, the expression of EGFR ligands is stringently 
regulated. In atypical cases, dysplasia could occur due to an increase in the expression of 
TGF-α or any other ligand belonging to the EGF family or due to a constitutively active 
mutation in the EGFR (Ji, et al., 2006). It has been reported that an elevation of EGFR 
expression is detected in 60 to 80% of cases of CRC (Goldstein & Armin, 2001). The 
higher its expression in several types of cancer the more aggressive the tumor would be 
and the poorer is its prognosis (Umekita, Ohi, Sagara, & Yoshida 2000). In human colon 
cancer, the level of TGF-α expression was observed to be four times more than that of 
normal mucosa (Liu, Woo, & Tsao, 1990). Similarly, an upregulation in the expression of 
TGF-α has been reported in many types of cancer compared to normal cells (Mellon, 
Cook, Chambers, & Neal, 1996).  
Several in vitro studies have showed TGF-α significantly increase the invasive 
ability of several types of cancer cell lines and this effect could be abolished almost 
completely by the additions of antibodies targeting the EGF receptor (Hölting, Siperstein, 
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Clark, & Duh, 1995; Ueda, et al., 1998).  In vivo studies showed that overexpression of 
TGF-α by colon cancer cells favors their progression and metastasis through the 
recruitment of cells that express VEGF, matrix metalloproteinases (MMPs), and 
interleukin-8 (IL-8), as well as by increasing metastasis to the lymphatic system (Sasaki, et 
al., 2008). These data provide sufficient evidence for the need to target the TGF-α/EGFR 
signaling pathway for therapeutic intervention. 
 
1.3.4. TGF-beta signaling pathway 
Transforming growth factors beta (TGF-β) are ligands that belong to the TGFβ 
superfamily. This superfamily includes cytokines such as activins, bone morphogenic 
proteins (BMPs), inhibins, and the anti-Müllerian hormone (Schmierer & Hill, 2007). 
TGF-β signaling plays a role in many cellular responses such as cell cycle arrest, 
migration, invasion, Epithelial to mesenchymal (EMT) transition, as well as immune 
suppression (Derynck, & Miyazono, 2008). Until recently, TGF-β signaling pathway was 
a paradox since it could promote cell proliferation but can also inhibit its growth, it could 
lead to stem cell differentiation but also enhances its pluripotency, and it suppresses pre-
malignant cells yet boosts metastatic ones. Current studies have shown that the response of 
a cell to the stimulation of TGF-β is dependent on three contextual determinants which are 
the epigenetic status of the cell, the proteins involved in the signaling transduction 
pathway, and the transcription factors present. Therefore, its effect varies among cell types 
and disease stage (Massagué, 2012). 
 
In normal cells, TGF-β suppresses tumorigenesis by causing cell cycle arrest and 
apoptosis, yet in advanced cancer, where it is usually overexpressed, the cells develop 
mutation in the TGF-β receptor or internal proteins that allow them to avoid the cytostatic 
and apoptotic effect and can even use the increase TGF-β expression to induce their own 
proliferation (Massagué, 2008). Also this increased ligand production promotes invasion 
of the cancer cells, through EMT transition and increased angiogenesis, and causes the 
recruitments of cells involved in inflammation, all of which leads to disease progression 
and metastasis  (Thiery, Acloque, Huang, & Nieto, 2009; Heldin, Vanlandewijck, & 
Moustakas, 2012). The effect of TGF-β is not only limited to the cancer cells but also has 
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potent effect on many immune system cells. It suppresses the proliferation of T cells and 
induces apoptosis in B cells (Ramesh, Wildey, & Howe, 2009).   
 
In colorectal cancer, TGF-β1 expression significantly increases with the 
advancement of cancer stage, invasive ability, and metastasis (Xiong, et al., 2002). TGF-
β1 overexpression is not only observed in tissues of the CRC but also it is also 
overexpressed in the patient’s serum (Tsushima, et al. 1996). In CRC, TGF-β also affects 
the microenvironment by modulating, immune system cells, endothelial and stromal cells 
as well as others which consequently would increase cell invasiveness (Elliott & Blobe, 
2005). 
Drugs that target the TGF-β signaling pathway have been designed and some are 
currently in Phase III clinical trials for the treatment of cancer. These drugs include 
monoclonal antibodies against the TGF-β receptor, ligand competitive peptides, inhibitors 
of TGF-β kinase activity, inhibitors of gene expression, as well as anti-sense 
oligonucleotides, the latter which have proceeded the furthest in clinical trials (Akhurst & 
Hata, 2012). Some adverse side effects for these drugs have been seen in pre-clinical trials 
but most were absent in clinical trials. The only adverse effects observed in clinical trials 
were the development of non-malignant skin lesion which disappears upon the withdrawal 
from the drug (Morris, J. C. et al, 2008) 
 
1.4. Motility, invasion, and metastasis of cancer cells 
The ability of cells to migrate is essential for the development and homeostasis of a 
multicellular organism. Cell motility is required during embryonic development to allow 
cells to reach their destined positions to properly form tissues and organs. Also in normal 
physiology, cells migrate to injured tissues to repair wounds, vascular endothelial cells 
move to create new capillaries, and white blood cells relocate to sites of inflammation to 
fight foreign organisms. Yet, pathological forms of migration exist in cancer cells, where 
these cells acquire the ability to migrate which is otherwise absent in their normal 
counterparts (Lauffenburger & Horwitz, 1996; Sheetz, Felsenfeld, Galbraith, Choquet, 
1999). Cell migration can be induced by either chemical or physical factors in the 
environment and comprises a complex process that involves the formation of a protrusion 
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at the leading side of the cell, followed by the creation of adhesions at the front edge, 
translocation of the cell, and then the retraction at the rear (Ridley, et al., 2003).  
Many studies have confirmed the involvement of cell motility in metastasis and in 
2010 alone more than a thousand published manuscripts have discussed this contribution. 
Whether it initially exists during diagnosis, or occurs during treatment or relapse, the 
dissemination of cancer cells from their primary site remains the primary cause of death in 
cancer patients (Palmer, Ashby, Lewis, & Zijlstra, 2011). Metastasis is a complex process 
not only limited to the ability of the cell to migrate but is dependent on the ability of the 
cell to invade neighboring tissues, intravasate nearby vasculature, survive in the blood or 
lymph, extravasate, and colonize at secondary sites (Fidler, 2003).  A very important step 
in metastasis is invasion which is not only dependent on capabilities of the cells 
themselves but also on the surrounding microenvironment. Cancer cells reorganize their 
microenvironment by secreting growth factors, cytokines, and matrix metalloproteinases. 
These signals would alter the extra cellular matrix and affect neighboring stromal cells 
such as macrophages, endothelial cells, and fibroblasts (Egeblad & Werb, 2002). In turn, 
these cells would release growth factors and other cytokines to enhance the invasion and 
proliferation of cancer cells (Alexander & Friedl, 2012). The early steps in the invasion 
process involves the activation of signaling pathways that modulate the cytoskeleton of the 
invasive cells and modifies cell-matrix and cell-cell junction which is then followed by the 
active migration of the cancer cells into nearby microenvironments (Friedl & Wolf, 2003). 
Targeting any step in the metastatic process such as motility or invasion can limit the 
metastatic ability of cancer cells and retain them in their primary location. 
 
1.5. Kefir 
1.5.1. Probiotics 
Recently because of the increasing need to find substitutes for conventional 
therapies, research has been directed toward the beneficial effects of probiotics and their 
potential role in the prevention and healing of various chronic diseases (Preidis et al. 2011; 
McNaught & MacFie, 2001). Probiotics have shown to exert beneficial effects on health 
and are now of great interest to the science community as well as to the food industry 
(Lopitz-Otsoa, Rementeria, Elguezabal, & Garaizar, J. 2006; Preidis et al. 2011). A 
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probiotic is either a single strain or a combination of different microorganisms claimed to 
positively affect the well-being of the host if ingested in adequate quantities (McNaught & 
Macfie, 2001). An example of probiotics is kefir, which is similar to yogurt in that it is a 
fermented milk beverage, but varies a lot in its constituents due to the fact that it produced 
by kefir grains (Lopitz-Otsoa et al. 2006).  
 
1.5.2. Characteristics and composition 
Kefir is an acidic drink containing small amounts of alcohol and is slightly 
carbonated (Lopitz-Otsoa et al. 2006). Kefir grains are a white, soft, gelatin-like mass 
composed of bacteria and yeast in a matrix of proteins, fat, and polysaccharides, with 
kefiran being the most important water-soluble polysaccharide (Lopitz-Otsoa et al. 2006). 
The yeasts and bacteria co-exist in a symbiotic relationship in the kefir grains and trying to 
culture different strains individually either inhibits their growth or decreases their 
biological activity which makes it difficult to examine the microbial population in the kefir 
grains (Lopitz-Otsoa et al. 2006). Kefir grains contain lactic acid bacteria (Lactobacillus 
delbruecki, Lactobacillus helveticus, Lactobacillus casei, Lactobacillus acidophilus, 
Lactobacillus brevis, etc.), yeasts (Saccharomyces sp., Candida, Torulopsis and 
Kluyveromyces), streptococci (Streptococcus salivarius), lactococci (Leuconostoc 
cremoris, Leuconostoc mesenteroides, Lactococcus lactis ssp. etc.) and infrequently acetic 
acid bacteria (Simova et al. 2005).  
 
1.5.3. Preparation of kefir 
The conventional method of producing kefir is by adding kefir grains to raw milk 
in a container and incubating them at room temperature for 24 hours. The fermented milk 
is filtered to retrieve the grains which would increase in biological mass, the grains can be 
used to inoculate a new batch of milk, and the process can be repeated continuously 
(Lopitz-Otsoa et al. 2006). To produce a new batch of kefir, it is essential to use kefir 
grains to inoculate the milk and not the previously produced kefir since the end product of 
the fermentation has a different microbiological profile from the kefir grains (Simova et al. 
2002). 
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1.5.4. Origin of kefir 
Kefir was produced for centuries in the Caucasus Mountains. Fresh milk from 
cows and goats were added to leather and goatskin sacs and allowed to ferment, then the 
fermented milk was removed and the sacs were replenished by fresh milk. After the 
continuous use of the same container, water-insoluble kefir grains started to form on the 
internal wall of the sac (Farnworth, 2005). 
 
1.5.5. Health benefits of kefir 
It has long been thought that kefir holds many healing powers for example the 
longevity of Bulgarian farmers has been assumed to be due their ingestion of kefir (Liu et 
al. 2002). Since the eighteenth century, many health benefits have been attributed to kefir 
including its ability to stimulate the immune system (Vinderola, Perdigón, Duarte, 
Farnworth, & Matar, 2006a), improve lactose digestion and tolerance in individuals with 
lactose intolerance (Hertzler & Clancy, 2003), decrease serum cholesterol levels (Liu et al. 
2006), act as an antifungal and antibacterial agent against many pathogenic organisms 
(Rodrigues, Caputo, Carvalho, Evangelista, & Schneedorf, 2005), provide resistance 
against enteric and diarrheal diseases (Preidis et al. 2011), in addition to its anti-tumoral 
activity (Chen, Chan, & Kubow, 2007). 
 
1.5.6. Anticancer effect 
1.5.6.1. In vivo studies 
The first publication to show an antitumoral activity of a water-soluble 
polysaccharide (KGF-C) separated from kefir grains was published in 1982 by Shiomi et 
al.  Whether this polysaccharide was administered orally or peritoneally it prevented the 
growth of Ehrlich carcinoma or Sarcoma 180 in comparison to control mice although its 
mode of action was elusive (Murofushi,  Shiomi, & Aibara, 1983; Shiomi, Sasaki, 
Murofushi, & Aibara, 1982). Later studies determined that KGF-C polysaccharide 
enhances the immune system by affecting T-cell and not B-cell action (Murofushi, 
Mizuguchi, Aibara, & Matuhasi, 1986). Additionally, studies have also shown that Lewis 
lung carcinoma and Ehrlich ascites carcinoma were both inhibited upon the oral 
administration of kefir (Furukawa, Matsuoka, & Yamanaka, 1990; Kubo, Odani, 
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Nakamura, Tokumaru, & Matsuda, 1992). Moreover, kefir produced from soy milk and 
cow’s milk considerably repressed tumor growth in mice injected with Sarcioma 180 as 
compared to unfermented milk and upon microscopic observations, it was suspected that 
the tumor size was decreased due to apoptosis (Liu, Wang, Lin, & Lin, 2002). 
 
1.5.6.2 In vitro studies 
In 2007, in vitro studies were performed on cell lines to determine whether kefir 
has any direct effect on cancer cells and its mode of action. Cell free kefir fractions 
exhibited an anti-proliferative effect on human mammary cancer cells (MCF-7) but did not 
affect normal human mammary epithelial cells (Chen et al. 2007). Similarly in vitro 
experiments using cell free kefir fractions showed anti-proliferative and pro-apoptotic 
effects on HTLV-1 (Human T-lymphotropic virus 1) positive and HTLV-1 negative T-
lymphocytes but did not exert any effect on lymphocytes removed from the peripheral 
blood of healthy individuals (Rizk, Maalouf, & Baydoun,  2009; Maalouf, Baydoun, & 
Rizk, 2011).  To better understand its mechanism of action, the levels of expression of 
transforming growth factors (TGFs) in the HTLV-1 negative cell lines CEM and Jurkat 
were determined using RT-PCR. When the CEM and Jurkat cell lines were treated with 
kefir, the levels of TGF-α which is a mitogen decreased whereas those of TGF-β which is 
usually a tumor suppressor in normal cells increased which is consistent with the observed 
anti-proliferative and pro-apoptotic effects of kefir. Moreover, in these cell lines the levels 
of MMP-2 and MMP-9 were evaluated using RT-PCR to examine the metastatic ability of 
the leukemic cell lines. No difference in the levels of MMP-2 was observed between 
control and treated cells whereas MMP-9 was not detected in either the control or the 
treated samples but this doesn’t rule out the effect of kefir on the metastatic ability of these 
cells (Maalouf et al. 2011). 
 
Recent work in our lab showed that kefir has anti-proliferative and pro-apoptotic 
effects on Caco-2 and HT-29 colorectal cell lines (unpublished data). This finding is 
important since earlier studies showed that the prevention of carcinogenesis by kefir and 
other probiotics was either through inducing changes in the intestinal microbiota that 
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inhibit the growth of bacteria converting pro-carcinogens into carcinogens or by 
modulating the immune response (LeBlac & Perdigo, 2010). 
 
1.5.6.3. Effect on metastasis 
Among the few studies that examine the anti-tumoral activity of kefir, only one 
work discusses the anti-metastatic ability of kefir on cancer cells in vivo. A study in 
2000 by Furukawa et al. showed that when the water-soluble polysaccharide fraction 
from kefir grains is administered orally either before or after tumor transplantation it 
inhibited the pulmonary metastasis of Lewis lung carcinoma. On the other hand, the 
water insoluble fraction of kefir grains was able to prevent metastasis in mice injected 
with the highly metastatic B16 melanoma cells compared to control mice (Furukawa, 
Matsuoka, Takahashi, & Yamanaka, 2000).  
 
1.6. Purpose of the study 
Until present the mechanism of action of kefir remains elusive, therefore the aim of 
this study is to determine a possible mechanism of action for the anti-proliferative and pro-
apoptotic effect seen upon the treatment of colorectal cancer cell lines with cell-free 
fractions of kefir. Moreover, since its effect on the motility and metastasis of cancer cells 
has not been thoroughly studied, the purpose of this study also involves determining the 
effect of cell-free fractions of kefir on the motility and invasion of colorectal and breast 
cancer cell in vitro. 
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Chapter II 
 
Materials and Methods 
 
2.1. Cell line and cell culture 
Two human colorectal adenocarcinoma cell lines, Caco-2 and HT-29, were 
cultured in DMEM medium supplemented with 10% FBS and 100U 
penicillin/streptomycin at 37°C and 5% CO2 in a humidified chamber. Human breast 
cancer cell lines (MCF-7 and MDA-MB231) obtained from ATCC (American Type 
Culture Collection), were cultured in DMEM medium supplemented with 10% FBS 
and 100U penicillin/streptomycin at 37°C and 5% CO2 in a humidified chamber.  
 
2.2 Preparation of kefir cell-free fraction and milk 
Sterilized, pasteurized skimmed milk (150 ml) was inoculated with kefir grains 
(50 g). Inoculated milk samples were incubated at 20°C for 24 hours in a sealed glass 
container. At the end of fermentation, the milk was strained to remove the kefir grains. 
The yeast and bacteria in the filtrate were removed by centrifugation (35,000 rpm for 
10 minutes at 4°C). The supernatant was stored at -20°C until needed for treatment of 
cells. On the day of treatment, the kefir was thawed and then passed through a 0.22-μm 
filter (Millipore, Billerica, MA). This cell free fraction of fermented milk, also termed 
kefir, was applied directly to the cells in different volumes to establish the different 
concentrations required. 
Sterilized, pasteurized skimmed milk was centrifuged (35,000 rpm for 10 
minutes at 4°C). The supernatant was stored at -20°C until needed for treatment of 
cells. On the day of treatment, the milk was thawed and then passed through a 0.45-μm 
filter and a 0.22-μm filter (Millipore, Billerica, MA) successively. The filtrate was 
applied directly to the cells in different volumes to establish the different 
concentrations required. 
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2.3 Antibodies and reagents 
Mouse monoclonal IgG anti-β-Actin, anti-Bax, anti-Bcl2, and anti-p53 
antibodies and rabbit polyclonal anti-p21 were obtained from Santa Cruz 
Biotechnology. Anti-mouse and anti-rabbit IgG HRP-conjugated secondary antibodies 
were obtained from Promega.  
 
2.4. Western blotting 
Cell lysates were prepared by scraping the cells in a sample buffer consisted of 
4% SDS, 10% β-mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, and 
0.125 M Tris-HCl at a pH of 6.8. The resulting lysates were boiled for 5 minutes. 
Protein samples were separated by SDS-PAGE on 10% (for Actin and P53) or 12% 
(for Bax, Bcl-2, and P21) gels and transferred to PVDF membranes overnight at 30V. 
The membranes were then blocked with 5% BSA (Bovine Serum Albumin) in PBS 
containing 0.1% Tween-20 for 1 hour at room temperature and incubated with primary 
antibody at a concentration of 1:1000 for 2 hours at room temperature. After the 
incubation with the primary antibody, the membranes were washed and incubated with 
secondary antibody at a concentration of 1:1000 for 1 hour at room temperature. The 
membranes were then washed, and the bands visualized by treating the membranes 
with western blotting enhanced chemiluminescent reagent ECL (GE Healthcare). The 
results were obtained on an X-ray film (Agfa Healthcare). The levels of protein 
expression were compared by densitometry using the ImageJ software.  
 
2.5. Reverse-transcription PCR 
Cells were grown in 6-well plate at density of 1x10
6 
cells/ml. After 24hrs, cells 
were treated with 0, 5, and 10% cell free fractions of kefir. 24hrs later, total RNA was 
extracted using RNeasy extraction kit (Qiagen) according to manufacturer’s 
instruction.  Reverse transcriptase polymerase chain reaction (RT-PCR) was used to 
amplify RNA of β-actin, TGF-α and TGF-β.  2µg of RNA was converted to cDNA 
using the OneStep RT-PCR kit (Qiagen) as described by the manufacturer. All gene-
specific primers designed to detect cDNA were obtained from Sigma-Aldrich. Primers 
for β-actin have the following sequences: Forward: 5’-
 17   
 
ATGAAGATCCTGACCGAGCGT-3’, Reverse: 5’-AACGCAGCTCAGTAACAGT-
CCG-3’. Primers for TGF-α have a forward sequence of: 5'- 
ATGTTGTTCCCTGCAAGTCC -3' and a reverse sequence of: 5'- 
ACTATGGAGAGGGGTCGCTT -3'. Primers for TGF-β Primers have a forward 
sequence of: 5’-GAAGTCACCCGCGTGCTAATGG -3’ and a reverse sequence of: 
3’- GGATGTAAACCTCGGACCTGTGTG -5’. All primers were used at a final 
concentration of 0.6 µM. Primers were added to 5X Qiagen OneStep RT-PCR buffer 
providing a final concentration of 2.5 mM MgCl2 in the reaction mix. A final 
concentration of 400µM of each dNTP was added along with 2.0 µL/reaction of 
enzyme mix. Final mastermix volume was adjusted to 50 µL using RNase-free water. 
Thermal cycler conditions, for both reverse transcription and PCR, was programmed 
as follows: reverse transcription at 50 
o
C for 30 min, initial PCR activation step at 
95
o
C for 15 min, followed by 30 cycles of denaturation at 94 
o
C for 1 min, annealing 
at: 52 
oC for β-actin, 48 °C for TGF-α and 50 oC for TGF-β1for 1min, and extension at 
72
o
C for 1min followed by a final extension step at 72 
o
C for 10min. From the PCR 
product, 10µL were run on 0.8% agarose gel stained with ethidium bromide at 100V 
for 30min. The resulting bands were visualized under UV light and photographed. β-
actin was used as a loading control. 
  
2.6. Wound Healing 
Cells were grown to confluence on culture plates and a wound was made in the 
monolayer with a sterile pipette tip. After wounding, the cells were washed twice with 
PBS to remove debris and new medium was added. Phase-contrast images of the 
wounded area were taken at 0 and 24 hours after wounding. Wound widths were 
measured at 11 different points for each wound, and the average rate of wound closure 
was calculated in m/hr using ImageJ software. 
 
2.7. Motility assay 
For motility analysis, images of cells moving randomly in serum were 
collected every 60 seconds for 2 hours using a 20X objective. During imaging, the 
temperature was controlled using a Nikon heating stage which was set at 37 °C. The 
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medium was buffered using HEPES and overlayed with mineral oil. The speed of cell 
movement was quantified using the ROI tracker plugin in the ImageJ software, which 
was used to calculate the total distance travelled by individual cells. The speed was 
then calculated by dividing this distance by the time (120 minutes) and reported in 
m/min. The speed of at least 10 cells for each condition was calculated.  
 
2.8. Invasion assay 
Cells were grown in 6-well plate. After 24 hrs, cells were treated with 0, 5, and 
10% cell free fractions of kefir for another 24 hrs. Invasion assay was performed 
following treatment period using the collagen-based invasion assay (Millipore) 
according to manufacturer’s instructions. Briefly, 24hrs prior to assay, cells were 
starved with serum free medium. Cells were harvested, centrifuged and then 
resuspended in quenching medium (without serum). Cells were then brought to a 
concentration of 1x10
6 
cells/ml. In the meantime, inserts were prewarmed with 300l 
of serum free medium for 30min at room temperature. After rehydration, 250l of 
media was removed from inserts and 250l of cell suspension was added. Inserts were 
then placed in a 24-well plate, and 500l of complete media (with 10% serum) was 
added to the lower wells. Plates were incubated for 24hrs at 37
o
C in a CO2 incubator. 
Following incubation period, inserts were stained for 20min at room temperature with 
400l of cell stain provided with the kit. Stain was then extracted with extraction 
buffer (also provided). 100ul of extracted stain was then transferred to a 96-well plate 
suitable for colorimetric measurement using a plate reader. Optical Density was then 
measured at 560m.  
 
2.8. Statistical analysis 
All the results reported represent average values from three independent 
experiments. All error estimates are given as ± SEM. The p-values were calculated by 
t-tests or chi-square tests depending on the experiment using the VassarStats: Website 
for Statistical Computation (http://vassarstats.net/).    
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Chapter III 
 
RESULTS 
 
3.1. Kefir reduces the expression of TGF-α and TGF-β in HT-29 cells: 
In order to determine a possible mechanism for the anti-proliferative effect of 
kefir observed in colorectal cancer cell lines, the expression of TGF-α and TGF-β1 
was assessed at the mRNA level using RT-PCR in HT-29 cells. The results showed a 
decrease in the expression of both cytokines in a dose dependent manner upon kefir 
treating HT-29 cells for 24hrs (Figure 1A). Yet, the expression of both cytokines did 
not change in milk treated cells (Figure 1B). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Expression of TGF-α and TGF-β1using reverse-transcription 
pcr in kefir and milk treated HT-29 cells. Figure 1A The expression of 
both cytokines in 0, 5, and 10% (v:v) kefir treated cells. Figure 1B The 
expression of both cytokines in 0, 5, and 10% (v:v) kefir treated cells.  
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3.2. Bax:Bcl-2 is increased in HT-29 cells 
To determine a possible mechanism of action for the pro-apoptotic effect of 
kefir on colorectal cancer cells, the expression of Bax and Bcl-2 was assessed at the 
protein level using western blot analysis. We observed an increase in the Bax:Bcl-2 
ratio upon kefir treatment while a slight decrease in this ratio was observed upon 
milk treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Fold increase in Bax:Bcl-2 expression in kefir and milk 
treated HT-29 cells. Figure 2A Western Blot analysis images for Bax 
and Bcl-2 in kefir treated cells. Figure 2B Western Blot analysis 
images for Bax and Bcl-2 in milk treated cells. Figure 2C Bar graph 
representing the fold increase in Bax:Bcl-2 expression in kefir and 
milk treated HT-29 cells relative to actin.  
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3.3. P21 but not P53 levels are increased in HT-29 cells upon kefir treatment 
To further elucidate the mechanism of action for the pro-apoptotic effect and 
anti-proliferative effect of kefir on colorectal cancer cells, the expression of P53 and 
P21 was assessed at the protein level using western blot analysis. The results showed 
no significant increase in the expression of P53 in kefir treated, yet p21 levels 
dramatically increased upon treating with 10% kefir. For milk treated cells, the 
expression of P53 and P21 does not vary between control and 10% treated cells. 
 
 
 
 
 
 
 
Figure 3. The expression of P21 and P53 in kefir and milk treated HT-29. Figure 
3A Western Blot analysis images for P21 and P53 in kefir treated cells. Figure 3B 
Western Blot analysis images for P21 and P53 in milk treated cells. Figure 3C Bar 
graph representing the fold increase in expression of P53 in kefir and milk treated 
cells relative to actin. Figure 3D Bar graph representing the fold increase in 
expression of P21 in kefir and milk treated cells relative to actin. 
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3.4. Kefir treatment does not affect the motility of HT-29 and Caco-2 cells 
The effect of kefir on the metastatic ability of cancer cells was only assessed 
once by Furukawa et al. in 2000 and the study was done in vivo. Therefore, we 
wanted to determine whether there is any direct effect on the motility of cancer cells 
in vitro upon kefir treatment and we started by looking at the motility of colorectal 
cancer cell lines Caco-2 and HT-29 using wound healing analysis. We observed no 
difference in the migration ability of control and kefir treated cells after 24 hrs of 
treatment (Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The migration ability of control and kefir-treated Caco-2 and HT-29 
cells in vitro using wound healing analysis. Figure 4A Images from the wound 
healing assay measuring the motility of HT-29 cells. Figure 4B Quantitation of the 
migration rate of figure 4A. Figure 4C Images from the wound healing assay 
measuring the motility of Caco-2 cells. Figure 4D Quantitation of the migration rate 
of figure 4C. Data are the mean ± SEM from 3 experiments. The results were not 
significant with p>0.05 
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3.5. Kefir treatment does not affect the motility of MCF-7 and MDA-MB-231 cells 
 
After observing no difference in the motility of CRC cells upon kefir treatment, we 
decided to explore whether kefir might induce an effect on the motility of other cancer 
types in vitro. Therefore we chose to look at MCF-7, breast cancer cells lines. We chose 
these cell lines in particular since the effect of cell-free fractions of kefir on MCF-7 has 
been previously established in 2007 by Chen et al. and it was also observed that kefir 
hindered the proliferative ability of these cells similar to our findings. And since we were 
looking at breast cancer cell lines, we also chose to explore the effect of kefir on another 
breast cancer cell line which is MDA-MB-231 cell line. In both of these cell lines, we 
observed a slight decrease in the migration ability between control and treated cells but the 
decrease was non-significant. 
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After observing no effect on the migration ability of MCF-7 and MDA-MB-231 
using the wound healing assay, we decided to assess the effect of kefir on their migration 
using a different assay known as time-lapse movie. Consistent with our previous results, 
we observed a slight decrease in the migration ability of both cell lines upon kefir 
treatment, yet the decrease was also non-significant. 
 
 
 
 
 
 
 
 
 
Figure 6. The migration ability of control and kefir-treated MCF-7 and MDA-MB-231 
cells in vitro using time-lapse movies. Figure 6A Migration path of the MCF-7 cells 
randomly moving in serum complete media for 2 hrs. Figure 6B. Bar graphs measuring the 
migration rate for the path traveled by MCF-7 cells in figure 6A. Figure 6C Migration path 
of the MDA-MB-231cells randomly moving in serum complete media for 2 hrs. Figure 
6D. Bar graphs measuring the migration rate for the path traveled by MDA-MB-231cells in 
figure 6C. Data are the mean ± SEM from 3 experiments. The results were not significant 
with p> 0.05 
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3.6. In vitro invasion of HT-29 cells is not affected by kefir treatment. 
After looking at the motility of colorectal and breast cancer cell lines in two-
dimensions and observing no effect upon kefir treatment, we decided to look at whether 
kefir has any effect on the invasive ability of the colorectal cancer cell line HT-29. Using 
the collagen-based invasion assay, we noticed no difference in the invasive ability of HT-
29 cell lines between control and 10% kefir treated cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. The invasive ability of control and kefir-treated HT-29 cells 
in vitro. Figure 7A Bar graph showing the absorbance of the stain 
retained by the invasive cells at 560nm which reflects the amount of 
invading cells. Figure 7B Representative images showing the collagen 
invading cells in purple which were seeded at a concentration of 
1x10
6
cells/ml and allowed to migrate toward 10% FBS containing media. 
Data are the mean ± SEM from 3 experiments. The results were not 
significant with p> 0.05 
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Chapter IV 
 
DISCUSSION 
 
It was always assumed among the Bulgarian farmers that kefir held special healing 
powers, and they believed that their longevity was attributed to their ingestion of kefir (Liu 
et al. 2002). Although kefir has been made in the Caucasus Mountains for hundreds of 
years, it was kept in secrecy within tribes who held it as their legacy, and not until recently 
has kefir grains been distributed to different regions of the world (Farnworth, 2005). Since 
then many studies have been made to confirm whether kefir has any health benefits, and 
these studies showed that kefir is able to enhance the immune system, inhibit the growth of 
pathogenic bacteria and fungi, decrease serum cholesterol levels, and most importantly 
have  antitumoral activity among other beneficial effects (Vinderola, et al., 2006a.; Liu et 
al. 2006; Rodrigues, et al. 2005; Chen, et al., 2007). Studies done in vivo showed that kefir 
is able to prevent the growth of tumors such as Sarcoma 180, Ehrlich carcinoma, as well 
Lewis lung carcinoma (Murofushi,  et al., 1983; Shiomi, et al., 1982). Yet its mechanism 
of action remained elusive and some data showed that this effect could be indirectly 
induced by kefir through the modulation of the immune system (Murofushi, et al., 1986). 
Since 2007, in vitro studies testing the effect of cell free fraction on breast and T-
lymphocyte cancer cell lines showed that kefir has anti-proliferative and pro-apoptotic 
effects on these cell lines (Chen et al. 2007; ). And similarly in 2009, a study performed by 
Rizk et al. showed the same effect on T-lymphocytes (Rizk, et al., 2009; Maalouf, et al., 
2011).   Our lab have recently showed that kefir have the same effects on Caco-2 and HT-
29 colorectal cell lines. So we aimed at trying to determine its possible mechanism of 
action. 
 
The expression of TGF-α and TGF-β1 at the mRNA level was first assessed to 
determine a possible explanation for the anti-proliferative effect of kefir. TGF-α is a 
known mitogen usually seen upregulated in many types of tumors especially CRC where 
its expression exceeds four times that of normal colorectal tissues.  TGF-α expression was 
downregulated in HT-29 cells upon kefir treatment in a dose dependent manner with 5 and 
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10% kefir (v:v) (Ji, et al., 2006; Liu, et al., 1990) (Figure 1A). These results are consistent 
with previous results in our lab showing a decrease in the proliferation of HT-29 and 
consistent with a previously published paper by Maalouf et al. in 2011. Moreover,  such 
observation is important knowing that TGF-α also plays a significant role in invasion and 
metastasis in vivo through the recruitment of cells expressing VEGF, interleukins, as well 
as MMPs, and when the TGF-α/EGFR receptor was targeted by antibodies, the invasive 
ability of CRC cells was abolished, (Sasaki, et al., 2008; Ueda, et al., 1998; Hölting, et al., 
1995). This further shows the importance of targeting TGF-α not only to inhibit cancer 
growth but also its invasion and metastasis.  
 
A downregulation in the expression level of TGF-β1 was noticed in HT-29 cells 
upon kefir treatment in a dose dependent manner (Figure 1A). These data were perplexing 
at the beginning since they contradicted a previously published paper by Maalouf at el. in 
2011 on HTLV-negative T-lymphocytes that showed an upregulation in TGF-β1 upon 
kefir treatment. TGF-β1 has long been assumed to act as a tumor suppressor yet many 
studies have shown data conflicting with its known role. Therefore recent studies found 
explanations for its dual role and demonstrated that the response of a cell to TGF-β1is 
context dependent and is affected by the epigenetic status of the cell, the proteins present 
in the signaling pathways, and by transcription factors (Massagué, 2012). In normal cells it 
is a tumor suppressor but in many cancers its overexpression is exploited by the cells and 
used as a mitogen (Massagué, 2008). In CRC TGF-β1 expression significantly increases 
with increased invasion and metastasis, therefore it could be an important target to limit its 
growth (Xiong, et al., 2002). Not only does it affect growth but TGF-β1 suppresses 
immune system cells in the microenvironment, recruits cells required for the invasion of 
CRC cells, induces EMT transition, and stimulates angiogenesis (Thiery, et al., 2012; 
Ramesh, et al., 2009). Therefore our data might be of great significance especially that 
drugs targeting the TGF-β signaling pathway especially through inhibiting the expression 
of TGF-β have now reached phase III clinical trials and the only observed side effect in 
clinical trials is the formation of non-malignant skin lesions that disappear after the 
withdrawal from the treatment (Akhurst & Hata, 2012; Morris, J. C. et al, 2008). The 
decrease of both cytokines was only observed in kefir and not milk treated cells which 
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confirms that it is either a single or a combination of end products from the fermentation 
which are inducing the effect and not components originally found in milk (Figure 1) 
 
To determine a possible explanation for the pro-apoptotic effect of kefir on CRC 
cell lines, we looked at the expression of Bax:Bcl-2 at the protein level using western blot 
analysis. Both of these proteins belong to the Bcl-2 family of protein where Bax acts as a 
pro-apoptotic protein whereas Bcl-2 acts as an anti-apoptotic protein (Wang, et al., 2009). 
It is generally considered that an increase in proportion of pro- to anti-apoptotic proteins 
signals a cell to undergo apoptosis (Ola, et al., 2011). In our findings, we noticed an 
upregulation in Bax:Bcl-2 expression in HT-29 cells consistent with the observed increase 
in apoptosis previously confirmed by our lab through the Cell-death ELISA based kit. For 
the milk treated cells, a decrease in Bax:Bcl-2 ratio was observed which is also in 
accordance with the  previously proven data in our lab showing a decrease in apoptosis 
and increase in proliferation in milk treated HT-29 cells (Figure 2).  
 
To further elucidate the mechanism of action of kefir, the expression levels of 
P53 and P21 proteins were assessed. P53 is known to induce cell cycle arrest and DNA 
repair and might also cause apoptosis in extremely damaged cells whereas P21, a target 
of P53, is a known cell cycle inhibitor that locks cells in the G1 phase (Oren & Rotter, 
1999; Harper, et al., 1993). For milk treated cells a slight decrease in P21 levels was 
observed. Treating cells with 5 and 10% kefir (v:v) led to a very slight increase in P53 
levels but a dramatic increase in P21 levels when treated with 10% kefir (v:v) (Figure 3). 
This increase in P21 levels might explain the cell cycle arrest observed at the G1 phase 
previously in our lab through cell cycle analysis by flow cytometry. Also our data 
suggest that P21 induction is P53-independent (Macleod, et al., 1995). Unpublished data 
in our lab also showed that kefir induce apoptosis in leukemic T-lymphocyte cell lines in 
a p-53 independent manner. 
 
Since metastasis is the main cause of death in cancer patients, and since the effect 
of kefir on metastasis has only been studied once before by Furukawa et al. in 2000, we 
wanted to assess the effect of cell-free fractions of kefir on the motility of CRC cancer cell 
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lines in vitro (Palmer, et al., 2011). Using wound-healing analysis, no difference in 
motility between the control and 10% kefir treated HT-29 and Caco-2 CRC cells was 
observed (Figure 4), yet these data contradict the previously published study in 2000 
which showed that kefir inhibited metastasis of Lewis lung carcinoma and B16 melanoma. 
The effect of cell free fractions of kefir were then assessed on weakly metastatic MCF-7 
and highly metastatic MDA-MB-231 breast cancer cell lines. Using both time-lapse 
movies and wound-healing assays to look at the motility of these two cells lines, we 
noticed a slight decrease in the motility of MCF-7 and MDA-MB-231 yet the decrease 
was non-significant (Figure 5 & 6). Yet metastasis does not depends only on the motility 
of the cells but also involves invasion of the microenvironment, intravasation into blood or 
lymphatic vessels, survival in the blood or lymph, extravasion, and colonization at 
secondary sites (Fidler, 2003).  Therefore, to determine whether kefir might be modulating 
the invasive ability of the cells as a mechanism for inhibiting metastasis, a collagen-based 
in vitro assay was performed. A decrease in the invasive ability of HT-29 cells was 
expected since a downregulation in the expression of TGF-α and TGF-β1 was observed 
upon kefir treatment, and knowing that they both play an important role in enhancing the 
invasive ability of cancer cells (Hölting, et al., 1995; Xiong, et al., 2002). Yet after 
performing the collagen-based invasion assay in vitro and no difference in the invasive 
ability between control and 10% treated cells was noticed (Figure 7). Thus an explanation 
for the contradiction observed between the motility and invasion data in vitro and that of 
the published article in 2000 could be explained by several hypotheses. One explanation 
could be that kefir is acting indirectly to inhibit metastasis in vivo by modulating the 
immune system. Another hypothesis could be that kefir might be intervening in other 
processes involved in metastasis beside motility and invasion. A third possibility is that 
components found in kefir might be modified in our body by enzymes leading to the 
formation of active compounds which are able to inhibit metastasis in vivo. 
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Chapter V 
CONCLUSION 
In this study we were the first to elucidate a potential mechanism of action for 
kefir’s effect on colorectal cancer in vitro as well as its effect on the motility and invasion. 
The downregulation in the expression of TGF-α and TGF-β1 explain the decrease in the 
proliferation of HT-29 cells in vitro. Also the observed overexpression of p21 which was 
seen to be p53-independent could be the reason behind the cell cycle arrest at the G1 phase 
previously seen upon kefir treatment. Moreover, we have seen that the expression of Bax 
to Bcl-2 at the protein level increases upon kefir treatment consistent with the increase in 
apoptosis induced by kefir. On the other hand, the effect of kefir on the motility and 
invasion of colorectal and breast cancer cell lines was insignificant, but this does not rule 
out the fact that kefir does have an effect on the metastatic ability of cancer cells. Kefir’s 
effect on metastasis could be by modulating other steps in the metastatic process or that its 
effect is only observed in vivo. Future plans are to confirm the effect of kefir on the growth 
of colorectal cancer in vivo and also to assess its effect on the metastasis of this cancer 
through the intrasplenic injection of HT-29 that causes liver metastasis. 
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